PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Deutsche Bank AG

PTC Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare genetic disorders. The company's lead product candidate is Translarna, an oral therapy for Duchenne muscular dystrophy (DMD), which has been granted orphan drug designation in the United States and Europe.

On August 10, 2021, Deutsche Bank AG announced that it had purchased approximately 5.3 million shares of PTC Therapeutics, Inc.'s common stock for a total purchase price of $47.9 million. This represents a significant investment in the company and its ongoing development efforts.

PTC Therapeutics, Inc. has been working to advance Translarna through clinical trials and regulatory approvals. The company has reported positive results from several studies, including a Phase 3 trial that demonstrated statistically significant improvements in motor function and quality of life measures compared to placebo in patients with DMD.

In addition to Translarna, PTC Therapeutics, Inc. is also developing other therapies for rare genetic disorders, including an oral therapy for cystic fibrosis and a gene therapy for spinal muscular atrophy. The company has a strong pipeline of potential therapies in various stages of development, which could provide significant growth opportunities in the future.

Overall, Deutsche Bank AG's investment in PTC Therapeutics, Inc.'s shares reflects the company's confidence in the potential of Translarna and its other therapies to address unmet medical needs for patients with rare genetic disorders.